Hepion appoints Michael Purcell to board as Audit Committee Chair

Hepion Pharmaceuticals, Inc.

Michael Purcell appointed as director of Hepion Pharmaceuticals on March 5, 2024.
Purcell named Chair of Audit Committee and member of Compensation and Corporate Governance/Nominations Committees.
No departures reported; Purcell fills a board vacancy.
Appointment effective immediately upon board vote.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Purcell

Director

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2024-03-05
Filed: March 6, 2024, 6:59 PM ET

On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Purcell was appointed as Director at Hepion Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company.

View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.